Epigenetic therapies such as DNA methyltransferase inhibitors, histone deacetylase inhibitors, EZH2, and BET inhibitors have shown promising results in preclinical models of PAH by improving pulmonary hemodynamics, reducing vascular remodeling, and increasing survival. The gene discussed is DNER; the disease is pulmonary arterial hypertension.